IMF TV

From our weekly series “Ask Dr. Durie” to comprehensive news from key cancer medical conferences around the world, IMF-TV is your all-access ticket to critical myeloma research, patient education and guidance. Check back often for regularly updated content. 

Oct
17
What are bispecific antibodies?
In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials to treat myeloma. BOTTOM LINE:​ Bispecific antibodies are showing(...)
Oct
11
How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients?
In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF). BOTTOM(...)
Oct
05
Living Well Teleconference: Clinical Trials in Myeloma
This teleconference will provide an overview of clinical trials and their importance in medicine. Issues addressed will include types of trials (phase 1, 2, 3…), how to interpret results of trials,(...)
Sep
19
The Impact of Nutrition on Side Effect Management
Did you know that what you eat can sometimes impact side effects experienced with myeloma and/or the various treatment regimens? Join our Living Well teleconference to hear from key experts who help(...)
Sep
17
Tiffany Williams
Tiffany Williams sees "the silver lining" of her multiple myeloma diagnosis, as "not taking time for granted...It’s the here. It’s the now. Tomorrow isn’t promise, and remembering that on a daily(...)
Sep
13
What is the latest on a new drug called selinexor?
In this week’s video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to(...)